WallStreetZenWallStreetZen

NASDAQ: RGEN
Repligen Corp Stock

$123.65-1.67 (-1.33%)
Updated Jun 24, 2024
RGEN Price
$123.65
Fair Value Price
$71.20
Market Cap
$6.91B
52 Week Low
$110.45
52 Week High
$211.13
P/E
441.61x
P/B
3.51x
P/S
16.89x
PEG
2.83x
Dividend Yield
N/A
Revenue
$607.45M
Earnings
$14.84M
Gross Margin
42.6%
Operating Margin
6.05%
Profit Margin
2.4%
Debt to Equity
0.45
Operating Cash Flow
$147M
Beta
1.07
Next Earnings
Jul 31, 2024
Ex-Dividend
N/A
Next Dividend
N/A

RGEN Overview

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RGEN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RGEN ($123.65) is overvalued by 73.67% relative to our estimate of its Fair Value price of $71.20 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RGEN ($123.65) is not significantly undervalued (73.67%) relative to our estimate of its Fair Value price of $71.20 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RGEN ($123.65) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RGEN due diligence checks available for Premium users.

Be the first to know about important RGEN news, forecast changes, insider trades & much more!

RGEN News

Valuation

RGEN fair value

Fair Value of RGEN stock based on Discounted Cash Flow (DCF)
Price
$123.65
Fair Value
$71.20
Overvalued by
73.67%
RGEN ($123.65) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RGEN ($123.65) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RGEN ($123.65) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RGEN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
441.61x
Industry
55.31x
Market
30.03x
RGEN is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
RGEN is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

RGEN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.51x
Industry
3.6x
RGEN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RGEN price to earnings growth (PEG)

For valuing profitable companies with growth potential
RGEN is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

RGEN's financial health

Profit margin

Revenue
$151.3M
Net Income
$2.1M
Profit Margin
1.4%
RGEN's Earnings (EBIT) of $36.73M... subscribe to Premium to read more.
Interest Coverage Financials
RGEN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$2.8B
Liabilities
$878.7M
Debt to equity
0.45
RGEN's short-term assets ($1.13B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RGEN's short-term assets ($1.13B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RGEN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RGEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$44.7M
Investing
-$8.4M
Financing
-$9.0M
RGEN's operating cash flow ($147.47M)... subscribe to Premium to read more.
Debt Coverage Financials

RGEN vs Medical Stocks

TickerMarket Cap1d %P/EP/B
RGEN$6.91B-1.33%441.61x3.51x
XRAY$5.31B+0.47%-59.47x1.63x
BLCO$5.25B+0.07%-15.56x0.79x
STVN$5.00B-4.83%30.89x3.50x
MMSI$4.85B+1.50%47.14x3.91x

Repligen Stock FAQ

What is Repligen's quote symbol?

(NASDAQ: RGEN) Repligen trades on the NASDAQ under the ticker symbol RGEN. Repligen stock quotes can also be displayed as NASDAQ: RGEN.

If you're new to stock investing, here's how to buy Repligen stock.

What is the 52 week high and low for Repligen (NASDAQ: RGEN)?

(NASDAQ: RGEN) Repligen's 52-week high was $211.13, and its 52-week low was $110.45. It is currently -41.43% from its 52-week high and 11.95% from its 52-week low.

How much is Repligen stock worth today?

(NASDAQ: RGEN) Repligen currently has 55,875,894 outstanding shares. With Repligen stock trading at $123.65 per share, the total value of Repligen stock (market capitalization) is $6.91B.

Repligen stock was originally listed at a price of $0.78 in Dec 31, 1997. If you had invested in Repligen stock at $0.78, your return over the last 26 years would have been 15,732.27%, for an annualized return of 21.51% (not including any dividends or dividend reinvestments).

How much is Repligen's stock price per share?

(NASDAQ: RGEN) Repligen stock price per share is $123.65 today (as of Jun 24, 2024).

What is Repligen's Market Cap?

(NASDAQ: RGEN) Repligen's market cap is $6.91B, as of Jun 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Repligen's market cap is calculated by multiplying RGEN's current stock price of $123.65 by RGEN's total outstanding shares of 55,875,894.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.